(Q33406813)

English

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

0 references

4

object named as

Maryam Fouladi

1 reference

Europe PubMed Central

26 July 2017

12

object named as

Susan M Blaney

1 reference

Europe PubMed Central

26 July 2017

author name string

Trent R Hummel

1

1 reference

Europe PubMed Central

26 July 2017

Lars Wagner

2

1 reference

Europe PubMed Central

26 July 2017

Charlotte Ahern

3

1 reference

Europe PubMed Central

26 July 2017

Joel M Reid

5

1 reference

Europe PubMed Central

26 July 2017

Renee M McGovern

6

1 reference

Europe PubMed Central

26 July 2017

Matthew M Ames

7

1 reference

Europe PubMed Central

26 July 2017

Richard J Gilbertson

8

1 reference

Europe PubMed Central

26 July 2017

Terzah Horton

9

1 reference

Europe PubMed Central

26 July 2017

Ashish M Ingle

10

1 reference

Europe PubMed Central

26 July 2017

Brenda Weigel

11

1 reference

Europe PubMed Central

26 July 2017

publication date

28 March 2013

1 reference

Europe PubMed Central

26 July 2017

Pediatric Blood Cancer

1 reference

Europe PubMed Central

26 July 2017

60

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

1452-1457

1 reference

Europe PubMed Central

26 July 2017

Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide in children with progressive low-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Discovery and development of SAHA as an anticancer agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

The epigenomics of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Role of temozolomide in pediatric brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Phase II trial of temozolomide in patients with progressive low-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Activity of temozolomide in the treatment of central nervous system tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

21 June 2018

Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Temozolomide treatment of an adult with a relapsing medulloblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Treatment of leptomeningeal relapse of medulloblastoma with temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Temozolomide in pediatric low-grade glioma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Phase I study of everolimus in pediatric patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24541

21 January 2018

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4139006

31 October 2018

Shortening the timeline of pediatric phase I trials: the rolling six design

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioanalytical method validation--a revisit with a decade of progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PBC.24541

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406813&oldid=1749478232"